1. Home
  2. PCRX vs WLDN Comparison

PCRX vs WLDN Comparison

Compare PCRX & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • WLDN
  • Stock Information
  • Founded
  • PCRX 2006
  • WLDN 1964
  • Country
  • PCRX United States
  • WLDN United States
  • Employees
  • PCRX N/A
  • WLDN N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • WLDN Military/Government/Technical
  • Sector
  • PCRX Health Care
  • WLDN Consumer Discretionary
  • Exchange
  • PCRX Nasdaq
  • WLDN Nasdaq
  • Market Cap
  • PCRX 1.2B
  • WLDN 1.6B
  • IPO Year
  • PCRX 2011
  • WLDN 2006
  • Fundamental
  • Price
  • PCRX $26.07
  • WLDN $102.06
  • Analyst Decision
  • PCRX Buy
  • WLDN Strong Buy
  • Analyst Count
  • PCRX 6
  • WLDN 2
  • Target Price
  • PCRX $30.00
  • WLDN $111.50
  • AVG Volume (30 Days)
  • PCRX 599.4K
  • WLDN 446.2K
  • Earning Date
  • PCRX 11-05-2025
  • WLDN 10-30-2025
  • Dividend Yield
  • PCRX N/A
  • WLDN N/A
  • EPS Growth
  • PCRX N/A
  • WLDN 94.22
  • EPS
  • PCRX N/A
  • WLDN 2.39
  • Revenue
  • PCRX $705,848,000.00
  • WLDN $628,172,000.00
  • Revenue This Year
  • PCRX $7.36
  • WLDN N/A
  • Revenue Next Year
  • PCRX $10.07
  • WLDN $9.00
  • P/E Ratio
  • PCRX N/A
  • WLDN $42.59
  • Revenue Growth
  • PCRX 2.25
  • WLDN 13.82
  • 52 Week Low
  • PCRX $13.42
  • WLDN $30.43
  • 52 Week High
  • PCRX $27.64
  • WLDN $121.00
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 51.80
  • WLDN 50.55
  • Support Level
  • PCRX $26.22
  • WLDN $96.14
  • Resistance Level
  • PCRX $27.50
  • WLDN $106.22
  • Average True Range (ATR)
  • PCRX 0.93
  • WLDN 5.15
  • MACD
  • PCRX -0.14
  • WLDN -1.48
  • Stochastic Oscillator
  • PCRX 21.89
  • WLDN 34.13

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

Share on Social Networks: